nnc0442-0344
Recombinant proteinexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 23, 2024 (NCT06649630)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Coagulation factor VIIISupplementation
F8 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07238816 | Phase 1 | Nov 18, 2025 | Novo Nordisk |
| NCT07220564 | Phase 1 | Oct 23, 2025 | Novo Nordisk |
| NCT06649630 | Phase 1 | Sep 23, 2024 | Novo Nordisk |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novo Nordisk | For profit | 3 | 3 | 1 | 2024 |
1 organizations
Page 1 / 1